NorthWest Biotherapeutics Inc (NWBO)

[Investor082]

BS. Kite could only produce for 100 patients in the first year after FDA approval of their product. Many examples of FDA approvals where volume manufacturing is not an issue, but quality always is.

But since you mention, it sounds like LP and LG have a very easy job to convince institutional investors and big pharma to financially back them at UK approval news? Who wouldn’t want a 20-30X return quickly? Let’s see what LP brings in that respect at UK approval. Don’t be blaming market makers or manipulators if she is unable to bring that backing right away and build sustained value from UK approval onwards.